CARBOPLATIN, BEVACIZUMAB, MK-4830, PACLITAXEL, KEYTRUDA 25 mg/mL concentrate for solution for infusion, DOCETAXEL
MK-4830-002
Phase 2 small_molecule active
Quick answer
CARBOPLATIN, BEVACIZUMAB, MK-4830, PACLITAXEL, KEYTRUDA 25 mg/mL concentrate for solution for infusion, DOCETAXEL for Primary peritoneal cancer/Fallopian tube cancer is a Phase 2 program (small_molecule) at Merck Sharp and Dohme with 1 ClinicalTrials.gov record(s).
Program details
- Company
- Merck Sharp and Dohme
- Indication
- Primary peritoneal cancer/Fallopian tube cancer
- Phase
- Phase 2
- Modality
- small_molecule
- Status
- active